Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025. Immutep Limited has released promising initial safety data for ...
CarBuzz on MSN
How automakers finally defeated turbo lag
Turbochargers are also prone to something called turbo lag, which is basically a delay in operation from throttle input to ...
Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab as a ...
SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...
In recent years, cancer research has undergone significant transformation, marked by the introduction of numerous innovative therapies. With the emergence of advanced PD-1/PD-L1 and CTLA-4 immune ...
Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial ...
Many of us have experienced jet lag after a holiday. But did you know you can have social jet lag as well? This happens when ...
Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback